Drug Transporter (DT) Information

General Information of DT
DT ID DTD0019
Gene Name SLC10A1
Protein Name Sodium/taurocholate cotransporting polypeptide
Gene ID
6554
UniProt ID
Q14973
TCDB ID
2.A.28.1.9
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms Cell growth-inhibiting gene 29 protein; NTCP; Na(+)/bile acid cotransporter; Na(+)/taurocholate transport protein; SLC10A1; Sodium/bile acid cotransporter; Solute carrier family 10 member 1
DT Family Bile Acid:Na(+) Symporter (BASS) Family ;
Function This tranporter strictly dependent on the extracellular presence of sodium and exhibits broad substrate specificity and transports various non-bile acid organic compounds as well.
Disease(s) Hypercholesterolemia [ICD-11: 5C80.0]
Hypothyroidism [ICD-11: 5A00.2]
Hyperlipidaemia [ICD-11: 5C8Z]
Endogenous Substrate(s) Bile acids; Bile conjugates; Steroids; Cholate; Tauroursodeoxycholate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Cerivastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [1]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [2]
Liothyronine
 Approved Drug Info Hypothyroidism 5A00.2 [3]
Pitavastatin calcium
 Approved Drug Info Dyslipidaemias 5C8Z [4]
Rosuvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [5]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [6]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [7]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Bile acid unspecific N.A. EM Info Identified using mouse NASH model [8]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Estrone sulfate Approved Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 27 microM [2]
Pitavastatin calcium Approved Drug Info Oocytes-NTCP Km = 15.1 microM [4]
Rosuvastatin Approved Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 65 microM [5]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Sodium taurocholate Preclinical Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 7.5 microM [2]
Sodium taurocholate Preclinical Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 7.9 microM [7]
Sodium taurocholate Preclinical Drug Info Human embryonic kidney cells (HEK293)-NTCP Km = 2.1 microM [6]
Taurocholic acid Terminated Drug Info Human cervical cancer cell line (Hela)-NTCP Km = 7.9 microM [7]
Taurocholic acid Terminated Drug Info Oocytes-NTCP Km = 6.2 microM [9]
References
1 Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
2 Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22.
3 Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501.
4 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
5 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
6 Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
7 Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
8 Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology. 2012 Jul;56(1):118-29.
9 Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.